Does the media prefer INO or YARW?

In the previous week, Inovio Pharmaceuticals and Inovio Pharmaceuticals both had 3 articles in the media. Inovio Pharmaceuticals' average media sentiment score of 0.59 beat Yarrow Bioscience's score of 0.00 indicating that Inovio Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inovio Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Yarrow Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor OTLK or YARW?

In the previous week, Oncobiologics had 9 more articles in the media than Yarrow Bioscience. MarketBeat recorded 12 mentions for Oncobiologics and 3 mentions for Yarrow Bioscience. Oncobiologics' average media sentiment score of 1.07 beat Yarrow Bioscience's score of 0.00 indicating that Oncobiologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oncobiologics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Yarrow Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer COYA or YARW?

In the previous week, Coya Therapeutics had 1 more articles in the media than Yarrow Bioscience. MarketBeat recorded 4 mentions for Coya Therapeutics and 3 mentions for Yarrow Bioscience. Coya Therapeutics' average media sentiment score of 0.64 beat Yarrow Bioscience's score of 0.00 indicating that Coya Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coya Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Yarrow Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to YARW or GUTS?

In the previous week, Fractyl Health had 10 more articles in the media than Yarrow Bioscience. MarketBeat recorded 13 mentions for Fractyl Health and 3 mentions for Yarrow Bioscience. Fractyl Health's average media sentiment score of 0.19 beat Yarrow Bioscience's score of 0.00 indicating that Fractyl Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Yarrow Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Fractyl Health 1 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ANIX or YARW?

In the previous week, Anixa Biosciences had 1 more articles in the media than Yarrow Bioscience. MarketBeat recorded 4 mentions for Anixa Biosciences and 3 mentions for Yarrow Bioscience. Yarrow Bioscience's average media sentiment score of 0.00 beat Anixa Biosciences' score of -0.63 indicating that Yarrow Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anixa Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Yarrow Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Yarrow Bioscience (YARW) Competitors

$39.25 -0.25 (-0.63%)

Closing price 04:00 PM Eastern

Extended Trading

$39.28 +0.02 (+0.06%)

As of 05:29 PM Eastern

Compare

YARW vs. INO, OTLK, COYA, GUTS, and ANIX

Should you buy Yarrow Bioscience stock or one of its competitors? Yarrow Bioscience's main competitors and comparable companies include Inovio Pharmaceuticals (INO), Oncobiologics (OTLK), Coya Therapeutics (COYA), Fractyl Health (GUTS), and Anixa Biosciences (ANIX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Yarrow Bioscience compare to Inovio Pharmaceuticals?

Inovio Pharmaceuticals (NASDAQ:INO) and Yarrow Bioscience (NASDAQ:YARW) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability, valuation and media sentiment.

Yarrow Bioscience has higher revenue and earnings than Inovio Pharmaceuticals. Yarrow Bioscience is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inovio Pharmaceuticals	N/A	N/A	-$84.95M	-$0.91	N/A
Yarrow Bioscience	$570K	183.86	-$26.48M	-$14.64	N/A

Inovio Pharmaceuticals presently has a consensus target price of $3.17, suggesting a potential upside of 145.48%. Yarrow Bioscience has a consensus target price of $58.00, suggesting a potential upside of 47.77%. Given Inovio Pharmaceuticals' higher possible upside, equities research analysts clearly believe Inovio Pharmaceuticals is more favorable than Yarrow Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inovio Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Yarrow Bioscience	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Inovio Pharmaceuticals has a net margin of 0.00% compared to Yarrow Bioscience's net margin of -4,726.21%. Yarrow Bioscience's return on equity of -84.40% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inovio Pharmaceuticals	N/A	-669.94%	-73.97%
Yarrow Bioscience	-4,726.21%	-84.40%	-77.68%

Inovio Pharmaceuticals has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market. Comparatively, Yarrow Bioscience has a beta of 1.95, suggesting that its stock price is 95% more volatile than the broader market.

26.8% of Inovio Pharmaceuticals shares are held by institutional investors. Comparatively, 83.8% of Yarrow Bioscience shares are held by institutional investors. 1.7% of Inovio Pharmaceuticals shares are held by company insiders. Comparatively, 3.0% of Yarrow Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Inovio Pharmaceuticals and Inovio Pharmaceuticals both had 3 articles in the media. Inovio Pharmaceuticals' average media sentiment score of 0.59 beat Yarrow Bioscience's score of 0.00 indicating that Inovio Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inovio Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Yarrow Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Inovio Pharmaceuticals beats Yarrow Bioscience on 8 of the 15 factors compared between the two stocks.

How does Yarrow Bioscience compare to Oncobiologics?

Oncobiologics (NASDAQ:OTLK) and Yarrow Bioscience (NASDAQ:YARW) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership, media sentiment and dividends.

Oncobiologics has a net margin of 0.00% compared to Yarrow Bioscience's net margin of -4,726.21%. Oncobiologics' return on equity of 0.00% beat Yarrow Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncobiologics	N/A	N/A	-254.82%
Yarrow Bioscience	-4,726.21%	-84.40%	-77.68%

11.2% of Oncobiologics shares are held by institutional investors. Comparatively, 83.8% of Yarrow Bioscience shares are held by institutional investors. 1.8% of Oncobiologics shares are held by insiders. Comparatively, 3.0% of Yarrow Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Yarrow Bioscience has lower revenue, but higher earnings than Oncobiologics. Yarrow Bioscience is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncobiologics	$1.35M	70.44	-$62.42M	-$0.77	N/A
Yarrow Bioscience	$570K	183.86	-$26.48M	-$14.64	N/A

Oncobiologics has a beta of 0.82, indicating that its share price is 18% less volatile than the broader market. Comparatively, Yarrow Bioscience has a beta of 1.95, indicating that its share price is 95% more volatile than the broader market.

In the previous week, Oncobiologics had 9 more articles in the media than Yarrow Bioscience. MarketBeat recorded 12 mentions for Oncobiologics and 3 mentions for Yarrow Bioscience. Oncobiologics' average media sentiment score of 1.07 beat Yarrow Bioscience's score of 0.00 indicating that Oncobiologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oncobiologics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Yarrow Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Oncobiologics currently has a consensus target price of $4.65, indicating a potential upside of 626.56%. Yarrow Bioscience has a consensus target price of $58.00, indicating a potential upside of 47.77%. Given Oncobiologics' higher probable upside, analysts plainly believe Oncobiologics is more favorable than Yarrow Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncobiologics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Yarrow Bioscience	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Oncobiologics beats Yarrow Bioscience on 8 of the 15 factors compared between the two stocks.

How does Yarrow Bioscience compare to Coya Therapeutics?

Coya Therapeutics (NASDAQ:COYA) and Yarrow Bioscience (NASDAQ:YARW) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, institutional ownership and risk.

Coya Therapeutics has a net margin of -270.22% compared to Yarrow Bioscience's net margin of -4,726.21%. Coya Therapeutics' return on equity of -52.05% beat Yarrow Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coya Therapeutics	-270.22%	-52.05%	-46.34%
Yarrow Bioscience	-4,726.21%	-84.40%	-77.68%

Coya Therapeutics currently has a consensus target price of $15.33, suggesting a potential upside of 204.23%. Yarrow Bioscience has a consensus target price of $58.00, suggesting a potential upside of 47.77%. Given Coya Therapeutics' higher possible upside, research analysts clearly believe Coya Therapeutics is more favorable than Yarrow Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Yarrow Bioscience	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Coya Therapeutics had 1 more articles in the media than Yarrow Bioscience. MarketBeat recorded 4 mentions for Coya Therapeutics and 3 mentions for Yarrow Bioscience. Coya Therapeutics' average media sentiment score of 0.64 beat Yarrow Bioscience's score of 0.00 indicating that Coya Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Coya Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Yarrow Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

39.8% of Coya Therapeutics shares are held by institutional investors. Comparatively, 83.8% of Yarrow Bioscience shares are held by institutional investors. 6.1% of Coya Therapeutics shares are held by company insiders. Comparatively, 3.0% of Yarrow Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Coya Therapeutics has higher revenue and earnings than Yarrow Bioscience. Coya Therapeutics is trading at a lower price-to-earnings ratio than Yarrow Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coya Therapeutics	$8.02M	14.74	-$21.23M	-$1.07	N/A
Yarrow Bioscience	$570K	183.86	-$26.48M	-$14.64	N/A

Coya Therapeutics has a beta of 0.6, suggesting that its share price is 40% less volatile than the broader market. Comparatively, Yarrow Bioscience has a beta of 1.95, suggesting that its share price is 95% more volatile than the broader market.

Summary

Coya Therapeutics beats Yarrow Bioscience on 11 of the 16 factors compared between the two stocks.

How does Yarrow Bioscience compare to Fractyl Health?

Yarrow Bioscience (NASDAQ:YARW) and Fractyl Health (NASDAQ:GUTS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, media sentiment, dividends, risk, institutional ownership and earnings.

Yarrow Bioscience presently has a consensus price target of $58.00, indicating a potential upside of 47.77%. Fractyl Health has a consensus price target of $5.12, indicating a potential upside of 553.23%. Given Fractyl Health's higher probable upside, analysts clearly believe Fractyl Health is more favorable than Yarrow Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Yarrow Bioscience	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Fractyl Health	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Yarrow Bioscience has a beta of 1.95, meaning that its stock price is 95% more volatile than the broader market. Comparatively, Fractyl Health has a beta of 2.32, meaning that its stock price is 132% more volatile than the broader market.

Yarrow Bioscience has higher revenue and earnings than Fractyl Health. Yarrow Bioscience is trading at a lower price-to-earnings ratio than Fractyl Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Yarrow Bioscience	$570K	183.86	-$26.48M	-$14.64	N/A
Fractyl Health	$90K	1,386.28	-$140.95M	-$0.88	N/A

Fractyl Health has a net margin of 0.00% compared to Yarrow Bioscience's net margin of -4,726.21%. Yarrow Bioscience's return on equity of -84.40% beat Fractyl Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Yarrow Bioscience	-4,726.21%	-84.40%	-77.68%
Fractyl Health	N/A	-1,362.10%	-84.89%

In the previous week, Fractyl Health had 10 more articles in the media than Yarrow Bioscience. MarketBeat recorded 13 mentions for Fractyl Health and 3 mentions for Yarrow Bioscience. Fractyl Health's average media sentiment score of 0.19 beat Yarrow Bioscience's score of 0.00 indicating that Fractyl Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Yarrow Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Fractyl Health	1 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

83.8% of Yarrow Bioscience shares are held by institutional investors. 3.0% of Yarrow Bioscience shares are held by insiders. Comparatively, 8.5% of Fractyl Health shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Fractyl Health beats Yarrow Bioscience on 10 of the 16 factors compared between the two stocks.

How does Yarrow Bioscience compare to Anixa Biosciences?

Anixa Biosciences (NASDAQ:ANIX) and Yarrow Bioscience (NASDAQ:YARW) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment.

Anixa Biosciences has a net margin of 0.00% compared to Yarrow Bioscience's net margin of -4,726.21%. Anixa Biosciences' return on equity of -71.12% beat Yarrow Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anixa Biosciences	N/A	-71.12%	-62.88%
Yarrow Bioscience	-4,726.21%	-84.40%	-77.68%

In the previous week, Anixa Biosciences had 1 more articles in the media than Yarrow Bioscience. MarketBeat recorded 4 mentions for Anixa Biosciences and 3 mentions for Yarrow Bioscience. Yarrow Bioscience's average media sentiment score of 0.00 beat Anixa Biosciences' score of -0.63 indicating that Yarrow Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anixa Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
Yarrow Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Anixa Biosciences presently has a consensus price target of $8.50, suggesting a potential upside of 132.24%. Yarrow Bioscience has a consensus price target of $58.00, suggesting a potential upside of 47.77%. Given Anixa Biosciences' higher possible upside, research analysts plainly believe Anixa Biosciences is more favorable than Yarrow Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anixa Biosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Yarrow Bioscience	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Anixa Biosciences has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market. Comparatively, Yarrow Bioscience has a beta of 1.95, suggesting that its share price is 95% more volatile than the broader market.

Anixa Biosciences has higher earnings, but lower revenue than Yarrow Bioscience. Anixa Biosciences is trading at a lower price-to-earnings ratio than Yarrow Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anixa Biosciences	$210K	592.92	-$10.93M	-$0.31	N/A
Yarrow Bioscience	$570K	183.86	-$26.48M	-$14.64	N/A

29.1% of Anixa Biosciences shares are held by institutional investors. Comparatively, 83.8% of Yarrow Bioscience shares are held by institutional investors. 26.4% of Anixa Biosciences shares are held by insiders. Comparatively, 3.0% of Yarrow Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Anixa Biosciences beats Yarrow Bioscience on 10 of the 16 factors compared between the two stocks.

Get Yarrow Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding YARW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

YARW vs. The Competition

Export

Metric	Yarrow Bioscience	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$104.80M	$4.04B	$7.31B	$12.78B
Dividend Yield	N/A	3.64%	2.54%	10.79%
P/E Ratio	-2.68	11.87	271.78	24.19
Price / Sales	183.86	1,430.05	696.74	129.13
Price / Cash	N/A	44.27	28.87	36.86
Price / Book	0.94	17.49	11.34	6.52
Net Income	-$26.48M	-$22.76M	$3.46B	$347.97M
7 Day Performance	-5.47%	4.71%	3.23%	1.57%
1 Month Performance	N/A	12.26%	8.82%	5.24%
1 Year Performance	N/A	60.84%	27.70%	17.87%

Yarrow Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
YARW Yarrow Bioscience	2.7892 of 5 stars	$39.25 -0.6%	$58.00 +47.8%	N/A	$104.80M	$570K	N/A	30	Analyst Upgrade Short Interest Increase
INO Inovio Pharmaceuticals	2.8417 of 5 stars	$1.20 +4.3%	$3.17 +163.9%	-36.2%	$112.70M	$60K	N/A	320
OTLK Oncobiologics	4.029 of 5 stars	$0.70 +4.1%	$4.65 +564.3%	-77.3%	$112.39M	$1.35M	N/A	20	Positive News
COYA Coya Therapeutics	2.8671 of 5 stars	$4.92 +5.4%	$15.33 +211.7%	-27.7%	$109.55M	$8.02M	N/A	6	Analyst Forecast
GUTS Fractyl Health	3.7735 of 5 stars	$0.72 +8.7%	$5.12 +614.0%	-26.5%	$108.24M	$90K	N/A	102	Trending News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:YARW) was last updated on 8/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Yarrow Bioscience (YARW) Competitors

YARW vs. INO, OTLK, COYA, GUTS, and ANIX

How does Yarrow Bioscience compare to Inovio Pharmaceuticals?

Summary

How does Yarrow Bioscience compare to Oncobiologics?

Summary

How does Yarrow Bioscience compare to Coya Therapeutics?

Summary

How does Yarrow Bioscience compare to Fractyl Health?

Summary

How does Yarrow Bioscience compare to Anixa Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

YARW vs. The Competition

Yarrow Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Yarrow Bioscience (YARW) Competitors

YARW vs. INO, OTLK, COYA, GUTS, and ANIX

How does Yarrow Bioscience compare to Inovio Pharmaceuticals?

Which has preferable earnings & valuation, INO or YARW?

Do analysts rate INO or YARW?

Is INO or YARW more profitable?

Which has more risk & volatility, INO or YARW?

Do insiders and institutionals hold more shares of INO or YARW?

Does the media prefer INO or YARW?

Summary

How does Yarrow Bioscience compare to Oncobiologics?

Is OTLK or YARW more profitable?

Do insiders & institutionals have more ownership in OTLK or YARW?

Which has better valuation & earnings, OTLK or YARW?

Which has more risk and volatility, OTLK or YARW?

Does the media favor OTLK or YARW?

Do analysts recommend OTLK or YARW?

Summary

How does Yarrow Bioscience compare to Coya Therapeutics?

Is COYA or YARW more profitable?

Do analysts recommend COYA or YARW?

Does the media prefer COYA or YARW?

Do insiders and institutionals hold more shares of COYA or YARW?

Which has higher valuation & earnings, COYA or YARW?

Which has more volatility & risk, COYA or YARW?

Summary

How does Yarrow Bioscience compare to Fractyl Health?

Do analysts rate YARW or GUTS?

Which has more volatility & risk, YARW or GUTS?

Which has better earnings & valuation, YARW or GUTS?

Is YARW or GUTS more profitable?

Does the media refer more to YARW or GUTS?

Do institutionals & insiders believe in YARW or GUTS?

Summary

How does Yarrow Bioscience compare to Anixa Biosciences?

Is ANIX or YARW more profitable?

Does the media favor ANIX or YARW?

Do analysts recommend ANIX or YARW?

Which has more risk and volatility, ANIX or YARW?

Which has stronger valuation & earnings, ANIX or YARW?

Do institutionals and insiders have more ownership in ANIX or YARW?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

YARW vs. The Competition

Yarrow Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools